Patents by Inventor Matthias Johannes Schnell

Matthias Johannes Schnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11975067
    Abstract: The present invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or portion thereof, and methods of use thereof.
    Type: Grant
    Filed: March 20, 2023
    Date of Patent: May 7, 2024
    Assignee: Thomas Jefferson University
    Inventors: Matthias Johannes Schnell, Christoph Wirblich, Drishya Kurup
  • Publication number: 20230398201
    Abstract: The present invention includes a vaccine comprising a nucleic acid comprising (a) a nucleotide sequence encoding a rabies virus nucleoprotein (N) or a portion thereof and (b) a nucleotide sequence encoding a glycoprotein (G) (e.g., a RABV glycoprotein, a MOKV glycoprotein, or a chimeric MOKV/RABY glycoprotein), or a portion thereof positioned immediately 3? to the nucleoprotein (N) gene sequence.
    Type: Application
    Filed: November 2, 2021
    Publication date: December 14, 2023
    Inventors: Matthias Johannes Schnell, Christoph Wirblich
  • Publication number: 20230338513
    Abstract: The present invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or portion thereof, and methods of use thereof.
    Type: Application
    Filed: March 20, 2023
    Publication date: October 26, 2023
    Inventors: Matthias Johannes Schnell, Christoph Wirblich, Drishya Kurup
  • Patent number: 11660336
    Abstract: The present invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or portion thereof, and methods of use thereof.
    Type: Grant
    Filed: August 5, 2022
    Date of Patent: May 30, 2023
    Assignee: Thomas Jefferson University
    Inventors: Matthias Johannes Schnell, Christoph Wirblich, Drishya Kurup
  • Publication number: 20230057428
    Abstract: The present invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or portion thereof, and methods of use thereof.
    Type: Application
    Filed: August 5, 2022
    Publication date: February 23, 2023
    Inventors: Matthias Johannes SCHNELL, Christoph WIRBLICH, Drishya KURUP
  • Patent number: 9249194
    Abstract: The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of the non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides methods for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: February 2, 2016
    Assignees: INSTITUT PASTEUR, THOMAS JEFFERSON UNIVERSITY
    Inventors: Christophe Prehaud, Monique Lafon, Matthias Johannes Schnell
  • Publication number: 20140341858
    Abstract: The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides means for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress.
    Type: Application
    Filed: June 23, 2014
    Publication date: November 20, 2014
    Inventors: Christophe PREHAUD, Monique LAFON, Matthias Johannes SCHNELL
  • Patent number: 8822665
    Abstract: The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides means for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: September 2, 2014
    Assignees: Institut Pasteur, Thomas Jefferson University
    Inventors: Christophe Prehaud, Monique Lafon, Matthias Johannes Schnell
  • Publication number: 20120100116
    Abstract: The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides means for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress.
    Type: Application
    Filed: April 2, 2010
    Publication date: April 26, 2012
    Applicants: THOMAS JEFFERSON UNIVERSITY, INSTITUT PASTEUR
    Inventors: Christophe Prehaud, Monique Lafon, Matthias Johannes Schnell